Logo image of BMRN

BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Fundamental Analysis

NASDAQ:BMRN - Nasdaq - US09061G1013 - Common Stock - Currency: USD

58.97  -0.2 (-0.34%)

Fundamental Rating

6

Taking everything into account, BMRN scores 6 out of 10 in our fundamental rating. BMRN was compared to 568 industry peers in the Biotechnology industry. BMRN gets an excellent profitability rating and is at the same time showing great financial health properties. A decent growth rate in combination with a cheap valuation! Better keep an eye on BMRN. This makes BMRN very considerable for value and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

In the past year BMRN was profitable.
BMRN had a positive operating cash flow in the past year.
Of the past 5 years BMRN 4 years were profitable.
BMRN had a positive operating cash flow in each of the past 5 years.
BMRN Yearly Net Income VS EBIT VS OCF VS FCFBMRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

1.2 Ratios

Looking at the Return On Assets, with a value of 6.11%, BMRN belongs to the top of the industry, outperforming 94.37% of the companies in the same industry.
BMRN has a better Return On Equity (7.54%) than 94.01% of its industry peers.
BMRN has a Return On Invested Capital of 7.44%. This is amongst the best in the industry. BMRN outperforms 94.72% of its industry peers.
BMRN had an Average Return On Invested Capital over the past 3 years of 3.73%. This is significantly below the industry average of 14.25%.
The 3 year average ROIC (3.73%) for BMRN is below the current ROIC(7.44%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.11%
ROE 7.54%
ROIC 7.44%
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
BMRN Yearly ROA, ROE, ROICBMRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

1.3 Margins

With an excellent Profit Margin value of 14.96%, BMRN belongs to the best of the industry, outperforming 95.77% of the companies in the same industry.
Looking at the Operating Margin, with a value of 19.85%, BMRN belongs to the top of the industry, outperforming 96.13% of the companies in the same industry.
BMRN's Gross Margin of 79.67% is amongst the best of the industry. BMRN outperforms 84.86% of its industry peers.
In the last couple of years the Gross Margin of BMRN has remained more or less at the same level.
Industry RankSector Rank
OM 19.85%
PM (TTM) 14.96%
GM 79.67%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
BMRN Yearly Profit, Operating, Gross MarginsBMRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

7

2. Health

2.1 Basic Checks

BMRN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for BMRN has been increased compared to 1 year ago.
Compared to 5 years ago, BMRN has more shares outstanding
The debt/assets ratio for BMRN has been reduced compared to a year ago.
BMRN Yearly Shares OutstandingBMRN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
BMRN Yearly Total Debt VS Total AssetsBMRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

BMRN has an Altman-Z score of 6.20. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
BMRN's Altman-Z score of 6.20 is amongst the best of the industry. BMRN outperforms 84.33% of its industry peers.
The Debt to FCF ratio of BMRN is 1.25, which is an excellent value as it means it would take BMRN, only 1.25 years of fcf income to pay off all of its debts.
BMRN's Debt to FCF ratio of 1.25 is amongst the best of the industry. BMRN outperforms 95.25% of its industry peers.
BMRN has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
BMRN has a worse Debt to Equity ratio (0.11) than 66.20% of its industry peers.
Even though the debt/equity ratio score it not favorable for BMRN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF 1.25
Altman-Z 6.2
ROIC/WACC0.75
WACC9.9%
BMRN Yearly LT Debt VS Equity VS FCFBMRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

A Current Ratio of 5.33 indicates that BMRN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.33, BMRN is in line with its industry, outperforming 57.92% of the companies in the same industry.
BMRN has a Quick Ratio of 3.29. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
BMRN has a Quick ratio (3.29) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.33
Quick Ratio 3.29
BMRN Yearly Current Assets VS Current LiabilitesBMRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

5

3. Growth

3.1 Past

BMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 132.63%, which is quite impressive.
Looking at the last year, BMRN shows a quite strong growth in Revenue. The Revenue has grown by 17.97% in the last year.
Measured over the past years, BMRN shows a quite strong growth in Revenue. The Revenue has been growing by 10.86% on average per year.
EPS 1Y (TTM)132.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%255.56%
Revenue 1Y (TTM)17.97%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%15.65%

3.2 Future

The Earnings Per Share is expected to grow by 27.94% on average over the next years. This is a very strong growth
Based on estimates for the next years, BMRN will show a small growth in Revenue. The Revenue will grow by 7.79% on average per year.
EPS Next Y47.7%
EPS Next 2Y36.64%
EPS Next 3Y33.45%
EPS Next 5Y27.94%
Revenue Next Year11.37%
Revenue Next 2Y10.65%
Revenue Next 3Y9.87%
Revenue Next 5Y7.79%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BMRN Yearly Revenue VS EstimatesBMRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B
BMRN Yearly EPS VS EstimatesBMRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 6

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 26.68, which means the current valuation is very expensive for BMRN.
Based on the Price/Earnings ratio, BMRN is valued cheaply inside the industry as 94.72% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 28.29, BMRN is valued at the same level.
A Price/Forward Earnings ratio of 18.07 indicates a rather expensive valuation of BMRN.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 94.37% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.32, BMRN is valued at the same level.
Industry RankSector Rank
PE 26.68
Fwd PE 18.07
BMRN Price Earnings VS Forward Price EarningsBMRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

BMRN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BMRN is cheaper than 95.25% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BMRN is valued cheaper than 95.07% of the companies in the same industry.
Industry RankSector Rank
P/FCF 23.78
EV/EBITDA 16
BMRN Per share dataBMRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BMRN may justify a higher PE ratio.
A more expensive valuation may be justified as BMRN's earnings are expected to grow with 33.45% in the coming years.
PEG (NY)0.56
PEG (5Y)N/A
EPS Next 2Y36.64%
EPS Next 3Y33.45%

More info and screens

0

5. Dividend

5.1 Amount

BMRN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOMARIN PHARMACEUTICAL INC

NASDAQ:BMRN (4/21/2025, 10:03:52 AM)

58.97

-0.2 (-0.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19 2025-02-19/amc
Earnings (Next)05-01 2025-05-01/amc
Inst Owners98.66%
Inst Owner Change0.37%
Ins Owners0.69%
Ins Owner Change6.79%
Market Cap11.31B
Analysts82.86
Price Target98.8 (67.54%)
Short Float %2.24%
Short Ratio2.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.32%
Min EPS beat(2)4.22%
Max EPS beat(2)18.43%
EPS beat(4)4
Avg EPS beat(4)27.65%
Min EPS beat(4)4.22%
Max EPS beat(4)57.23%
EPS beat(8)6
Avg EPS beat(8)17.96%
EPS beat(12)9
Avg EPS beat(12)-7.1%
EPS beat(16)13
Avg EPS beat(16)20.46%
Revenue beat(2)2
Avg Revenue beat(2)3.56%
Min Revenue beat(2)2.69%
Max Revenue beat(2)4.42%
Revenue beat(4)3
Avg Revenue beat(4)2.54%
Min Revenue beat(4)-2.4%
Max Revenue beat(4)5.44%
Revenue beat(8)4
Avg Revenue beat(8)0.47%
Revenue beat(12)6
Avg Revenue beat(12)-0.15%
Revenue beat(16)8
Avg Revenue beat(16)0.39%
PT rev (1m)-0.42%
PT rev (3m)-0.13%
EPS NQ rev (1m)-0.09%
EPS NQ rev (3m)14.97%
EPS NY rev (1m)5.42%
EPS NY rev (3m)7.48%
Revenue NQ rev (1m)-0.11%
Revenue NQ rev (3m)2.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.14%
Valuation
Industry RankSector Rank
PE 26.68
Fwd PE 18.07
P/S 3.96
P/FCF 23.78
P/OCF 19.74
P/B 2
P/tB 2.17
EV/EBITDA 16
EPS(TTM)2.21
EY3.75%
EPS(NY)3.26
Fwd EY5.54%
FCF(TTM)2.48
FCFY4.2%
OCF(TTM)2.99
OCFY5.07%
SpS14.88
BVpS29.51
TBVpS27.15
PEG (NY)0.56
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 6.11%
ROE 7.54%
ROCE 8.88%
ROIC 7.44%
ROICexc 9.06%
ROICexgc 9.91%
OM 19.85%
PM (TTM) 14.96%
GM 79.67%
FCFM 16.66%
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF 1.25
Debt/EBITDA 0.9
Cap/Depr 101.03%
Cap/Sales 3.41%
Interest Coverage 54.69
Cash Conversion 86.4%
Profit Quality 111.38%
Current Ratio 5.33
Quick Ratio 3.29
Altman-Z 6.2
F-Score8
WACC9.9%
ROIC/WACC0.75
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)132.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%255.56%
EPS Next Y47.7%
EPS Next 2Y36.64%
EPS Next 3Y33.45%
EPS Next 5Y27.94%
Revenue 1Y (TTM)17.97%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%15.65%
Revenue Next Year11.37%
Revenue Next 2Y10.65%
Revenue Next 3Y9.87%
Revenue Next 5Y7.79%
EBIT growth 1Y258.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year84.98%
EBIT Next 3Y19.03%
EBIT Next 5Y23.16%
FCF growth 1Y820.51%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y259.69%
OCF growth 3Y23.45%
OCF growth 5Y63.99%